Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
Joseph SassineFareed KhawajaTerri Lynn ShigleVictoria HandyFarnaz FooladSamuel L AitkenYing JiangRichard ChamplinElizabeth ShpallKaty RezvaniElla J Ariza-HerediaRoy F ChemalyPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
Primary letermovir prophylaxis effectively prevents refractory or resistant CMV infections and decreases nonrelapse mortality at week 48, as well as CS-CMVi and CMV disease after allogeneic HCT.